Aspire Biopharma Holdings (ASBP) Cash from Financing Activities (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Cash from Financing Activities for 6 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $8.4 million in Q2 2026; TTM through Jun 2026 was $19.1 million, a 518.75% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, up 2199.19% from the prior year.
• Cash from Financing Activities was $8.4 million for Q2 2026 at Aspire Biopharma Holdings, up from $7.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $296.6 million in Q1 2022 and troughed at -$632968.0 in Q3 2023.
• A 5-year average of $26.6 million and a median of $360780.5 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 416.0% in 2024 and jumped 1250.79% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at $296.6 million in 2022, then slumped by 99.95% to $155848.0 in 2023, then slumped by 416.0% to -$492477.0 in 2024, then soared by 96.64% to -$16526.0 in 2025, then jumped by 51085.03% to $8.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $8.4 million (Q2 2026), $7.9 million (Q1 2026), and -$16526.0 (Q4 2025), per Business Quant data.